This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.
Nature · 2026
PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.
Blood · 2026
The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
Clinical lymphoma, myeloma & leukemia · 2023
Latest funding
- $990,676
Understanding inevitable relapse of multiple myeloma following highly-effective anti-BCMA treatment
CIHR · 2020 · Principal investigator
- $32,300
Expediting Patient-Oriented Research in Canada: Development of Myeloma Canada Research Network (MCRN)
CIHR · 2015 · Principal investigator
- $361,800
A small molecule inhibitor of G protein-coupled Receptor Kinase 6 (GRK6) to treat human Multiple Myeloma and related diseases
CIHR · 2011 · Nominated PI
27 publications.
Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.
St Paul M, Hendrikse LD, Ying F, Snow BE, Luo P, Helke S, Smith LK, Hilal A, Abelman DD, Ramamurthy N, Nault H, Wei EN, Gold MJ, Tobin C, Lien SC, Liu Y, Zhou W, Zhang X, Nguyen D, Agbede O, Pedersen S, Eagles J, Saunders ME, Berger T, Wakeham A, Scott DS, Ly D, de Campos CB, Liang G, Zheng C, Wilson WV, Masih-Khan E, White D, McCurdy A, Louzada ML, Kotb R, Chu MP, Parkin S, Reece D, Gul E, Tiedemann R, Pugh TJ, Hirano N, Ohashi PS, Stewart AK, Trudel S, Mak TW
PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism.
Bonolo de Campos C, He R, Pelino T, Abelman DD, Li Z, Lee DKC, Wang DY, St Paul M, Bruce J, Simpson CD, Wybeng-Groot L, Moran MF, Tiedemann R, Pugh T, Mak TW, Issakova O, Sepetov N, Trudel S, Stewart AK
The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma.
Lebel E, Lajkosz K, Masih-Khan E, Reece D, Trudel S, Tiedemann R, Prica A, Kukreti V, Chen C
Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression.
Croucher DC, Devasia AJ, Abelman DD, Mahdipour-Shirayeh A, Li Z, Erdmann N, Tiedemann R, Pugh TJ, Trudel S
Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?
Khan S, Reece D, Atenafu EG, Bhella S, Chen C, Masih-Khan E, Paul H, Prica A, Tiedemann R, Trudel S, Kukreti V
Kinetics of response to first- and second-line therapies in multiple myeloma: Assessment by both M-spikes and light chains.
Lebel E, Li X, Paul H, Masih-Khan E, Bhella S, Chen C, Prica A, Reece D, Tiedemann R, Trudel S, Kukreti V
Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis.
Rivera Duarte A, Reece D, Li X, Xu W, Paul H, Masih-Khan E, Winter A, Tiedemann R, Prica A, Chen C, Trudel S, Kukreti V
A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Monteith BE, Venner CP, Cheung MC, Pater J, Shepherd L, Richardson H, Reece D, Gul E, Lalancette M, Castonguay V, Kukreti V, Tiedemann R, Phua C, Bhella S, Dudebout J, Sherry M, Yen H, Chen BE, Hay AE
Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma.
Lebel E, Chen C, Paul H, Trudel S, Tiedemann R
Syngeneic transplants for multiple myeloma - a single center experience and review of the literature.
Lebel E, Prica A, Bhella S, Kukreti V, Tiedemann R, Trudel S, Reece D, Chen C
Understanding inevitable relapse of multiple myeloma following highly-effective anti-BCMA treatment
Principal investigators: Pugh, Trevor J; Tiedemann, Rodger; Trudel, Suzanne M
Keywords: Cancer Genomics; Circulating Tumour Dna; Multiple Myeloma; Single Cell Sequencing; Translational Research
Expediting Patient-Oriented Research in Canada: Development of Myeloma Canada Research Network (MCRN)
Principal investigators: Reece, Donna E; Del Col, Aldo; Bahlis, Nizar J; Reiman, Tony; Tiedemann, Rodger
Keywords: Clinical Trials Network; Cost Effective Analyses; Innovative Diagnostics; Innovative Therapy Approaches; Knowledge Translation; Multiple Myeloma; Myeloma Patient Database Development; Patient-Oriented Quality Of Life; Personalized Medicine; Transitional (Bench To Bedside) Research
A small molecule inhibitor of G protein-coupled Receptor Kinase 6 (GRK6) to treat human Multiple Myeloma and related diseases
Principal investigators: Tiedemann, Rodger
Keywords: Cancer; Crystallography; Drug Development; G Protein Coupled Receptor Kinase 6; Genomics; High Throughput Screening; Kinase Inhibitor; Lymphoma; Multiple Myeloma; Novel Therapeutics
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Biostatistics Division
- Department of Medical Biophysics
- Department of Medicine
- Department of Laboratory Medicine and Pathobiology
- Radiation Oncology
- Tumor Immunology
- Medicine
- Other
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Suzanne Trudel
Faculty
23 shared papers, latest 2026
Donna Reece
Faculty
9 shared papers, latest 2026
Wei Xu
Biostatistics Division
2 shared papers, latest 2022
Xuan Li
Biostatistics Division
2 shared papers, latest 2022
Naoto Hirano
Tumor Immunology
1 shared papers, latest 2026
John Kuruvilla
Faculty
1 shared papers, latest 2019
Arleigh McCurdy
Department of Medicine
1 shared papers, latest 2026
Christine Cserti-Gazdewich
Department of Laboratory Medicine and Pathobiology
1 shared papers, latest 2013
Trevor Pugh
Department of Medical Biophysics
1 shared papers, latest 2026
Shereen Ezzat
Medicine
1 shared papers, latest 2007
Fei-Fei Liu
Radiation Oncology
1 shared papers, latest 2018
Laurie Ailles
Department of Medical Biophysics
1 shared papers, latest 2018
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.